311 related articles for article (PubMed ID: 33248395)
1. Parkinson's disease and skin.
Niemann N; Billnitzer A; Jankovic J
Parkinsonism Relat Disord; 2021 Jan; 82():61-76. PubMed ID: 33248395
[TBL] [Abstract][Full Text] [Related]
2. Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Novelli A; Di Vico IA; Terenzi F; Sorbi S; Ramat S
Parkinsonism Relat Disord; 2019 Jul; 64():352-353. PubMed ID: 31101554
[No Abstract] [Full Text] [Related]
3. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
4. Use of advanced therapies for Parkinson's disease in Norway.
Ezat B; Pihlstrøm L; Aasly J; Tysnes OB; Egge A; Dietrichs E
Tidsskr Nor Laegeforen; 2017 May; 137(9):619-623. PubMed ID: 28468476
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine in the treatment of Parkinson's disease: a review.
Pessoa RR; Moro A; Munhoz RP; Teive HAG; Lees AJ
Arq Neuropsiquiatr; 2018 Dec; 76(12):840-848. PubMed ID: 30698208
[TBL] [Abstract][Full Text] [Related]
6. The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.
Skorvanek M; Bhatia KP
Mov Disord Clin Pract; 2017; 4(1):21-31. PubMed ID: 30363435
[TBL] [Abstract][Full Text] [Related]
7. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Richter D; Bartig D; Jost W; Jörges C; Stumpe B; Gold R; Krogias C; Tönges L
J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
[TBL] [Abstract][Full Text] [Related]
9. Advanced Parkinson's disease: clinical characteristics and treatment. Part II.
Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
Neurologia; 2013; 28(9):558-83. PubMed ID: 23880230
[TBL] [Abstract][Full Text] [Related]
10. [Prevention and treatment of fluctuations in patients with Parkinson's disease].
Ludin HP; Surber Ch
Praxis (Bern 1994); 2006 Dec; 95(51-52):2013-8. PubMed ID: 17294589
[TBL] [Abstract][Full Text] [Related]
11. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
12. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
13. [Treatment possibilities in advanced Parkinson's disease].
Takáts A; Nagy H; Radics P; Tóth A; Tamás G
Ideggyogy Sz; 2013 Nov; 66(11-12):365-71. PubMed ID: 24555235
[TBL] [Abstract][Full Text] [Related]
14. [The treatment of Parkinson's disease].
Baumann CR; Waldvogel D
Praxis (Bern 1994); 2013 Dec; 102(25):1529-35. PubMed ID: 24326048
[TBL] [Abstract][Full Text] [Related]
15. [Selection of the optimal device-aided therapy in Parkinson's disease].
Kovács N; Aschermann Z; Juhász A; Harmat M; Pintér D; Janszky J
Ideggyogy Sz; 2019 Jan; 72(1-2):5-11. PubMed ID: 30785241
[TBL] [Abstract][Full Text] [Related]
16. [Continuous and advanced treatment strategies in the old to very old parkinsonian population].
Mariani LL
Geriatr Psychol Neuropsychiatr Vieil; 2020 Jun; 18(2):177-186. PubMed ID: 32338612
[TBL] [Abstract][Full Text] [Related]
17. Current strategies in the treatment of Parkinson's disease and a personalized approach to management.
Diaz NL; Waters CH
Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137
[TBL] [Abstract][Full Text] [Related]
18. When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Worth PF
Pract Neurol; 2013 Jun; 13(3):140-52. PubMed ID: 23487815
[TBL] [Abstract][Full Text] [Related]
19. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
20. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
